2022-500540-38-00已完成1 期
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
EU Legal Representative
Scientific
Novartis Pharma AG
研究点 (5)
Loading locations...
相似试验
招募中
1 期
A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.2023-504949-31-00AstraZeneca AB37
招募中
1 期
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers2024-518889-27-00SmartDyeLivery GmbH48
已完成
1 期
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema2023-503683-16-00Breye Therapeutics ApS3
招募中
1 期
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease2023-504412-14-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG20